CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Coherus Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOQTORZI | $48.95M | $45.29M | $40.84M | $36.00M | $30.66M | $24.49M | $19.13M | – | – | – | – | – | 96.1% | +59.6% |
| Other revenue | $1.99M | $1.59M | $1.34M | $1.16M | $977.00K | $7.19M | $7.26M | $7.17M | $7.15M | $901.00K | $664.00K | $650.00K | 3.9% | +103.8% |
| Total net product revenue | – | – | – | – | – | – | $259.70M | $297.18M | $300.99M | $300.97M | $256.58M | $210.42M | – | – |
| UDENYCA | – | – | – | – | – | – | $205.95M | $195.86M | $162.74M | $143.55M | $127.06M | $129.18M | – | – |
| CIMERLI | – | – | – | – | – | – | $27.08M | $79.43M | $120.68M | $147.41M | $125.39M | – | – | – |
| YUSIMRY | – | – | – | – | – | – | $7.54M | $9.72M | $11.23M | – | $3.57M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Coherus Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.